Pembrolizumab With or Without Bevacizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Open-Label, Phase 2 Trial (The Lancet Oncology, Feb 2025)
Wan-Qin Chong, MBBS a ∙ Jia-Li Low, MBBS a ∙ Joshua K Tay, PhD b,d ∙ Thi Bich Uyen Le, BSca ∙ Grace Shi-Qing Goh, BSc g ∙ Kenneth Sooi, MBBS a ∙ Hui-Lin Teo, MBBS h ∙ Seng-Wee Cheo, MD a ∙ Regina Tong-Xin Wong, BSc g ∙ Jens Samol, MD h,j,k ∙ Ming-Yann Lim, MBBS i ∙ Hao Li, MBBS i ∙ Niranjan Shirgaonkar, MSc l ∙ Shumei Chia, PhD l ∙ Lingzhi Wang, PhD f,g ∙ Anil Gopinathan, MBBS c ∙ Donovan Kum-Chuen Eu, MBBS b ∙ Raymond King-Yin Tsang, MBChB b,d ∙ Prof Kwok-Seng Loh, MBBS b,d ∙ Prof Han-Chong Toh, MBBS m ∙ Nicholas Syn, MBBSe ∙ Li-Ren Kong, PhD f,g ∙ Ramanuj Dasgupta, PhD l ∙ Bee-Choo Tai, PhD n ∙ Yaw-Chyn Lim, PhD …
